Literature DB >> 10527073

Antitumor effect of vaccinia virus in glioma model.

T M Timiryasova1, J Li, B Chen, D Chong, W H Langridge, D S Gridley, I Fodor.   

Abstract

The ability of certain viruses to lyse cancer cells suggests that they may have potential as oncolytic agents. We investigated the effect of vaccinia virus (VV) and its recombinant derivatives (recVV2, rVV-p53) on growth of C6 rat glioma cells that form fast growing tumors in athymic nude mice. VV effectively infected C6 cells in vitro, inducing high level of foreign gene expression. Most of C6 cells infected in vitro with rVV-p53 expressing the tumor suppressor p53 protein showed apoptosis specific morphological changes in DAPI-stained nuclei and DNA fragmentation pattern on gel electrophoresis; infection with VV induced low level of cell apoptosis. In an ex vivo experiment, VV-infected C6 cells were implanted s.c. in athymic nude mice and tumor development was monitored. In contrast to the control PBS group, most of mice implanted with infected cells remained tumor free until the end of the observation period. In an in vivo experiment, injection of VV or rVV-p53 after the C6 cells had been implanted in nude mice induced effective inhibition of tumor growth in comparison with control PBS groups. The oncolytic effect was greater with rVV-p53, apparently due to overexpressed p53 and p53-mediated cell apoptosis. In study of virus virulence we did not observe disease symptoms in athymic mice infected with a high dose of VV. Experimental results indicate that vaccinia virus itself and vaccinia-mediated delivery of therapeutic genes represent novel potential strategies for tumor therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527073

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  16 in total

1.  Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.

Authors:  Marianne M Stanford; John W Barrett; Steven H Nazarian; Steven Werden; Grant McFadden
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

2.  Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential.

Authors:  Guido Wollmann; Peter Tattersall; Anthony N van den Pol
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  Replicating poxviruses for human cancer therapy.

Authors:  Manbok Kim
Journal:  J Microbiol       Date:  2015-04-08       Impact factor: 2.902

Review 4.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15

5.  Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Authors:  XueQing Lun; Jennifer Chan; Hongyuan Zhou; Beichen Sun; John J P Kelly; Owen Owen Stechishin; John C Bell; Kelley Parato; Kang Hu; Dominique Vaillant; Jiahu Wang; Ta-Chiang Liu; Caroline Breitbach; David Kirn; Donna L Senger; Peter A Forsyth
Journal:  Mol Ther       Date:  2010-08-31       Impact factor: 11.454

6.  Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma.

Authors:  Wen Lei; Shibing Wang; Chunmei Yang; Xianbo Huang; Zhenzhen Chen; Wei He; Jianping Shen; Xinyuan Liu; Wenbin Qian
Journal:  Sci Rep       Date:  2016-08-24       Impact factor: 4.379

7.  Establishing elements of a synthetic biology platform for Vaccinia virus production: BioBrick™ design, serum-free virus production and microcarrier-based cultivation of CV-1 cells.

Authors:  Shuchang Liu; Ludmila Ruban; Yaohe Wang; Yuhong Zhou; Darren N Nesbeth
Journal:  Heliyon       Date:  2017-02-04

Review 8.  Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.

Authors:  Dana Haddad
Journal:  Front Oncol       Date:  2017-05-23       Impact factor: 6.244

Review 9.  Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.

Authors:  Amish C Shah; Dale Benos; G Yancey Gillespie; James M Markert
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

Review 10.  Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses.

Authors:  Giacomo G Vecil; Frederick F Lang
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.